A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer.

MLA

Picus, Joel, et al. “A Phase 2 Study of Estramustine, Docetaxel, and Bevacizumab in Men with Castrate-Resistant Prostate Cancer.” Cancer (0008543X), vol. 117, no. 3, Feb. 2011, pp. 526–33. EBSCOhost, https://doi.org/10.1002/cncr.25421.

APA

Picus, J., Halabi, S., Kelly, W. K., Vogelzang, N. J., Whang, Y. E., Kaplan, E. B., Stadler, W. M., & Small, E. J. (2011). A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer. Cancer (0008543X), 117(3), 526–533. https://doi.org/10.1002/cncr.25421

Chicago

Picus, Joel, Susan Halabi, W. Kevin Kelly, Nicholas J. Vogelzang, Young E. Whang, Ellen B. Kaplan, Walter M. Stadler, and Eric J. Small. 2011. “A Phase 2 Study of Estramustine, Docetaxel, and Bevacizumab in Men with Castrate-Resistant Prostate Cancer.” Cancer (0008543X) 117 (3): 526–33. doi:10.1002/cncr.25421.